The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism

Bruce C, Beamer LJ, Tall AR: The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol. 1998, 8: 426-434. 10.1016/S0959-440X(98)80118-8. Day JR, Albers JJ, Lofton-Day CE, Gilbert TL, Ching AF, Grant FJ, O'Hara PJ, Marcovina SM, Adolphson JL: Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem. 1994, 269: 9388-9391. Massey JB, Hickson D, She HS, Sparrow JT, Via DP, Gotto AM, Pownall HJ: Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim Biophys Acta. 1984, 794: 274-280. 10.1016/0005-2760(84)90156-5. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, Miller NE, Metso J, Olkkonen VM, Ehnholm C, Jauhiainen M, Hattori H: Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res. 2000, 41: 1651-1657. Siggins S, Karkkainen M, Tenhunen J, Metso J, Tahvanainen E, Olkkonen VM, Jauhiainen M, Ehnholm C: Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. J Lipid Res. 2004, 45: 387-395. Cheung MC, Albers JJ: Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins. J Lipid Res. 2006, 47: 1315-1321. 10.1194/jlr.M600042-JLR200. Jiang XC, Bruce C: Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem. 1995, 270: 17133-17138. 10.1074/jbc.270.29.17133. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC: Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem. 2002, 277: 39561-39565. 10.1074/jbc.M207187200. Valenta DT, Ogier N, Bradshaw G, Black AS, Bonnet DJ, Lagrost L, Curtiss LK, Desrumaux CM: Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol. 2006, 26: 1572-1578. 10.1161/01.ATV.0000225700.43836.ae. Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M: Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res. 2006, 47: 1725-1732. 10.1194/jlr.M600051-JLR200. Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, Ehnholm C, Curtiss LK: Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res. 2003, 44: 1453-1461. 10.1194/jlr.M200281-JLR200. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, Marcovina S, Wight TN, Chait A, Albers JJ: Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 2003, 108: 270-274. 10.1161/01.CIR.0000079163.97653.CD. Yazdanyar A, Jiang XC: Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low density lipoprotein production. Hepatology. 2012, 56: 576-10.1002/hep.25648. 584. Tu AY, Albers JJ: Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes. 2001, 50: 1851-1856. 10.2337/diabetes.50.8.1851. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP: Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes. 1999, 48: 1631-1637. 10.2337/diabetes.48.8.1631. Riemens SC, Van Tol A, Stulp BK, Dullaart RP: Influence of insulin sensitivity and the TaqIB cholesteryl ester transfer protein gene polymorphism on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men. J Lipid Res. 1999, 40: 1467-1474. Lalanne F, Motta C, Pafumi Y, Lairon D, Ponsin G: Modulation of the phospholipid transfer protein-mediated transfer of phospholipids by diacylglycerols. J Lipid Res. 2001, 42: 142-149. Tu AY, Albers JJ: Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene. Biochem Biophys Res Commun. 2001, 287: 921-926. 10.1006/bbrc.2001.5687. Tu AY, Chen H, Johnson KA, Paigen B, Albers JJ: Characterization of the mouse gene encoding phospholipid transfer protein. Gene. 1997, 188: 115-118. 10.1016/S0378-1119(96)00793-7. Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P: The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol. 2003, 23: 2182-2191. 10.1128/MCB.23.6.2182-2191.2003. Murdoch SJ, Wolfbauer G, Kennedy H, Marcovina SM, Carr MC, Albers JJ: Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res. 2002, 43: 281-289. Okazaki H, Goldstein JL, Brown MS, Liang G: LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem. 2010, 285: 6801-6810. 10.1074/jbc.M109.079459. Huuskonen J, Wohlfahrt G, Jauhiainen M, Ehnholm C, Teleman O, Olkkonen VM: Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. J Lipid Res. 1999, 40: 1123-1130. Kawano K, Qin SC, Lin M, Tall AR, Jiang XC: Cholesteryl ester transfer protein and phospholipid transfer protein have no overlapping functions in vivo. J Biol Chem. 2000, 275: 29477-29481. 10.1074/jbc.M003523200. Tollefson JH, Ravnik S, Albers JJ: Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J Lipid Res. 1988, 29: 1593-1602. Tall AR, Hogan V, Askinazi L, Small DM: Interaction of plasma high density lipoproteins with dimyristoyllecithin multilamellar liposomes. Biochemistry. 1978, 17: 322-326. 10.1021/bi00595a020. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ: Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res. 1985, 26: 842-851. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C: Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993, 268: 4032-4036. Huuskonen J, Olkkonen VM, Ehnholm C, Metso J, Julkunen I, Jauhiainen M: Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion. Biochemistry. 2000, 39: 16092-16098. 10.1021/bi0019287. Rye KA, Jauhiainen M, Barter PJ, Ehnholm C: Triglyceride-enrichment of high density lipoproteins enhances their remodeling by phospholipid transfer protein. J Lipid Res. 1998, 39: 613-622. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB: Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem. 1997, 272: 27393-27400. 10.1074/jbc.272.43.27393. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC: Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol. 2003, 23: 1601-1607. 10.1161/01.ATV.0000085841.55248.13. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR: Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996, 98: 2373-2380. 10.1172/JCI119050. van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R: Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol. 2000, 20: 1082-1088. 10.1161/01.ATV.20.4.1082. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999, 103: 907-914. 10.1172/JCI5578. Qin S, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, Jiang X: Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hyper catabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res. 2000, 41: 269-276. Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC: PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res. 2004, 45: 1852-1858. 10.1194/jlr.M400053-JLR200. Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ: Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem. 2003, 278: 52379-52385. 10.1074/jbc.M310695200. Oram JF, Wolfbauer G, Tang C, Davidson WS, Albers JJ: An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J Biol Chem. 2008, 283: 11541-11549. 10.1074/jbc.M800117200. Moerland M, Samyn H, van Gent T, van Haperen R, Dallinga-Thie G, Grosveld F, van Tol A, de Crom R: Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol. 2008, 28: 1277-1282. 10.1161/ATVBAHA.108.165084. Samyn H, Moerland M, van Gent T, van Haperen R, Grosveld F, van Tol A, de Crom R: Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 2009, 204: 429-434. 10.1016/j.atherosclerosis.2008.10.020. Vikstedt R, Metso J, Hakala J, Olkkonen VM, Ehnholm C, Jauhiainen M: Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. Biochemistry. 2007, 46: 11979-11986. 10.1021/bi700833h. Moerland M, Samyn H, van Gent T, Jauhiainen M, Metso J, van Haperen R, Grosveld F, van Tol A, de Crom R: Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. J Lipid Res. 2007, 48: 2622-2631. 10.1194/jlr.M700020-JLR200. de Vries R, Groen AK, Perton FG, Dallinga-Thie GM, van Wijland MJ, Dikkeschei LD, Wolffenbuttel BH, van Tol A, Dullaart RP: Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis. 2008, 196: 733-741. 10.1016/j.atherosclerosis.2006.12.027. Attia N, Nakbi A, Smaoui M, Chaaba R, Moulin P, Hammami S, Hamda KB, Chanussot F, Hammami M: Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. Tohoku J Exp Med. 2007, 213: 129-137. 10.1620/tjem.213.129. Lagor WR, Brown RJ, Toh SA, Millar JS, Fuki IV, de la Llera-Moya M, Yuen T, Rothblat G, Billheimer JT, Rader DJ: Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Arterioscler Thromb Vasc Biol. 2009, 29: 40-46. 10.1161/ATVBAHA.108.177105. Young SG: Recent progress in understanding apolipoprotein B. Circulation. 1990, 82: 1574-1594. 10.1161/01.CIR.82.5.1574. Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M: Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science. 1987, 238: 363-366. 10.1126/science.3659919. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J: A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 1987, 50: 831-840. 10.1016/0092-8674(87)90510-1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973, 52: 1544-1568. 10.1172/JCI107332. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 1983, 24: 147-155. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B: Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000, 30: 685-694. 10.1046/j.1365-2362.2000.00702.x. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR: Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord. 1998, 22: 414-423. 10.1038/sj.ijo.0800602. Rustaeus S, Stillemark P, Lindberg K, Gordon D, Olofsson SO: The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J Biol Chem. 1998, 273: 5196-5203. 10.1074/jbc.273.9.5196. Boren J, Rustaeus S, Olofsson SO: Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J Biol Chem. 1994, 269: 25879-25888. Wang Y, McLeod RS, Yao Z: Normal activity of microsomal triglyceride transfer protein is required for the oleate-induced secretion of very low density lipoproteins containing apolipoprotein B from McA-RH7777 cells. J Biol Chem. 1997, 272: 12272-12278. 10.1074/jbc.272.19.12272. Hamilton RL, Wong JS, Cham CM, Nielsen LB, Young SG: Chylomicron-sized lipid particles are formed in the setting of apolipoprotein B deficiency. J Lipid Res. 1998, 39: 1543-1557. Lang CA, Davis RA: Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes. J Lipid Res. 1990, 31: 2079-2086. Wang H, Chen X, Fisher EA: N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. J Clin Invest. 1993, 91: 1380-1389. 10.1172/JCI116340. Sparks JD, Sparks CE: Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem. 1990, 265: 8854-8862. Gibbons GF, Khurana R, Odwell A, Seelaender MC: Lipid balance in HepG2 cells: active synthesis and impaired mobilization. J Lipid Res. 1994, 35: 1801-1808. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, Tall AR: Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med. 2001, 7: 847-852. 10.1038/89977. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Lankhuizen I, van Tol A: Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res. 2002, 43: 1875-1880. 10.1194/jlr.M200166-JLR200. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O'Connor J, Van Tol A: Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes. 2002, 51: 3300-3305. 10.2337/diabetes.51.11.3300. Masson D, Deckert V, Gautier T, Klein A, Desrumaux C, Viglietta C, Pais de Barros JP, Le Guern N, Grober J, Labbe J, Menetrier F, Ripoll PJ, Leroux-Coyau M, Jolivet G, Houdebine LM, Lagrost L: Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein. Arterioscler Thromb Vasc Biol. 2011, 31: 766-774. 10.1161/ATVBAHA.110.215756. Liu R, Iqbal J, Yeang C, Wang DQ, Hussain MM, Jiang XC: Phospholipid transfer protein-deficient mice absorb less cholesterol. Arterioscler Thromb Vasc Biol. 2007, 27: 2014-2021. 10.1161/ATVBAHA.107.149914. Jiang XC, Tall AR, Qin S, Lin M, Schneider M, Lalanne F, Deckert V, Desrumaux C, Athias A, Witztum JL, Lagrost L: Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem. 2002, 277: 31850-31856. 10.1074/jbc.M205077200. Ogier N, Klein A, Deckert V, Athias A, Bessede G, Le Guern N, Lagrost L, Desrumaux C: Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol supplementation. Arterioscler Thromb Vasc Biol. 2007, 27: 2407-2412. 10.1161/ATVBAHA.107.151753. Jiang XC, Li Z, Liu R, Yang XP, Pan M, Lagrost L, Fisher EA, Williams KJ: Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem. 2005, 280: 18336-18340. Dullaart RP, de Vries R, Dallinga-Thie GM, Sluiter WJ, van Tol A: Phospholipid transfer protein activity is determined by type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin Endocrinol (Oxf). 2008, 68: 375-381. Miller SI, Ernst RK, Bader MW: LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005, 3: 36-46. 10.1038/nrmicro1068. Hailman E, Albers JJ, Wolfbauer G, Tu AY, Wright SD: Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem. 1996, 271: 12172-12178. 10.1074/jbc.271.21.12172. Gautier T, Klein A, Deckert V, Desrumaux C, Ogier N, Sberna AL, Paul C, Le Guern N, Athias A, Montange T, Monier S, Piard F, Jiang XC, Masson D, Lagrost L: Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem. 2008, 283: 18702-18710. 10.1074/jbc.M802802200. Erdmann J, Grosshennig A, Braund PS, Konig IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D, Merlini PA, Peyvandi F, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, Zeller T: New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009, 41: 280-282. 10.1038/ng.307. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC: A common allele on chromosome 9 associated with coronary heart disease. Science. 2007, 316: 1488-1491. 10.1126/science.1142447. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P: Genomewide association analysis of coronary artery disease. N Engl J Med. 2007, 357: 443-453. 10.1056/NEJMoa072366. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008, 40: 161-169. 10.1038/ng.76. Vergeer M, Boekholdt SM, Sandhu MS, Ricketts SL, Wareham NJ, Brown MJ, de Faire U, Leander K, Gigante B, Kavousi M, Hofman A, Uitterlinden AG, van Duijn CM, Witteman JC, Jukema JW, Schadt EE, van der Schoot E, Kastelein JJ, Khaw KT, Dullaart RP, van Tol A, Trip MD, Dallinga-Thie GM: Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation. 2010, 122: 470-477. 10.1161/CIRCULATIONAHA.109.912519. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009, 41: 56-65. 10.1038/ng.291. van Tol A: Phospholipid transfer protein. Curr Opin Lipidol. 2002, 13: 135-139. 10.1097/00041433-200204000-00004. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, Jiang XC: High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2003, 23: 1857-1862. 10.1161/01.ATV.0000094433.98445.7F. Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC: Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis. 2009, 207: 261-265. 10.1016/j.atherosclerosis.2009.04.011. Chen X, Sun A, Mansoor A, Zou Y, Ge J, Lazar JM, Jiang XC: Plasma PLTP activity is inversely associated with HDL-C levels. Nutr Metab (Lond). 2009, 6: 49-10.1186/1743-7075-6-49. Schgoer W, Mueller T, Jauhiainen M, Wehinger A, Gander R, Tancevski I, Salzmann K, Eller P, Ritsch A, Haltmayer M, Ehnholm C, Patsch JR, Foeger B: Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 2008, 196: 219-226. 10.1016/j.atherosclerosis.2007.04.046. van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, Grosveld F, de Crom R: Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem. 2002, 277: 48938-48943. 10.1074/jbc.M209128200. Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, Jauhiainen M, Van Eck M: Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol. 2007, 27: 578-586. 10.1161/01.ATV.0000254815.49414.be. van Haperen R, Samyn H, Moerland M, van Gent T, Peeters M, Grosveld F, van Tol A, de Crom R: Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One. 2008, 3: e2255-10.1371/journal.pone.0002255. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC: Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27: 190-196. 10.1161/01.ATV.0000249721.96666.e5. Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK: Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J Lipid Res. 2008, 49: 24-32. 10.1194/jlr.M700228-JLR200.